Why is ethnicity important in cardiovascular care?

Ski, Chantal F.; Fitzsimons, Donna; King‐Shier, Kathryn

doi:10.1177/1474515117741892

Cited by 6 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…49 A strategy to reduce these inequalities is to take a holistic approach encompassing not only pharmacogenomic diversity but also differences in lifestyle, health-care provision, socio-economic-cultural determinants, and/or CV risk profiles. 50 …”

Section: Discussionmentioning

confidence: 99%

Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events

Tamargo

Kaski

Kimura

et al. 2022

European Heart Journal - Cardiovascular Pharmacotherapy

View full text Add to dashboard Cite

Awareness of racial/ethnic disparities represents a key challenge for healthcare systems that attempt to provide effective healthcare and to reduce existing inequalities in the use of and adherence to guideline-recommended cardiovascular drugs to improve clinical outcomes for cardiovascular disease (CVD). In this review, we describe important racial/ethnic differences between and within ethnic groups in the prevalence, risk factors, haemostatic factors, anti-inflammatory and endothelial markers, recurrence, and outcomes of CVD. We discuss important differences in the selection, doses, and response [efficacy and adverse drug reactions (ADRs)] in ethnically diverse patients treated with antithrombotics or lipid-lowering drugs. Differences in drug response are mainly related to racial/ethnic differences in the frequency of polymorphisms in genes encoding drug-metabolizing enzymes (DMEs) and drug transporters. These polymorphisms markedly influence the pharmacokinetics, dose requirements, and safety of warfarin, clopidogrel, and statins. This review aims to support a better understanding of the genetic differences between and among populations to identify patients who may experience an ADR or a lack of drug response, thus optimizing therapy and improving outcomes. The greater the understanding of the differences in the genetic variants of DMEs and transporters that determine the differences in the exposure, efficacy, and safety of cardiovascular drugs between races/ethnicities, the greater the probability that personalized medicine will become a reality.

show abstract

Section: Discussionmentioning

confidence: 99%

Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events

Tamargo

Kaski

Kimura

et al. 2022

European Heart Journal - Cardiovascular Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…13 Insufficient knowledge of cultural differences in patients with heart disease can lead to differential treatment and referral patterns. 16 Qualitative systematic reviews recommended further studies to explore the experiences of living with HF among people in ethnic minority groups. 17 18 Most previous research on HF is based on quantitative measurement and sparse qualitative studies that consider patient or partner separately; however, relatively little is known about families' experiences of living with HF, particularly in ethnic minority families.…”

Section: Introductionmentioning

confidence: 99%

Living with heart failure: perspectives of ethnic minority families

2020

View full text Add to dashboard Cite

BackgroundThe family perspective on heart failure (HF) has an important role in patients’ self-care patterns, adjustment to the disease and quality of life. Little is known about families’ experiences of living with HF, particularly in ethnic minority families. This study describes the experiences of Iranian families living with HF as an ethnic minority family in Denmark.MethodsIn this descriptive qualitative study, we conducted eight face-to-face joint family interviews of Iranian patients with HF and their family members living in Denmark. We used content analysis with an inductive approach for data analysis.ResultsWe identified three categories: family daily life, process of independence and family relationships. Families were faced with physical restrictions, emotional distress and social limitations in their daily lives that threatened the patients’ independence. Different strategies were used to promote independence. One strategy was normalisation and avoiding the sick role; another strategy was accepting and adjusting themselves to challenges and limitations. The independence process itself had an impact on family relationships. Adjusting well to the new situation strengthened the relationship, while having problems in adjustment strained the relationship within the family.ConclusionsThis study highlights the process of independence as perceived by families living with HF. It is crucial to both families and healthcare professionals to maintain a balance between providing adequate support and ensuring independence when dealing with patients with HF. Understanding patients’ stories and their needs seems to be helpful in gaining this balance.

show abstract

“…6 The burden of diabetes and atherosclerotic CVD complications is distributed disproportionately, several ethnic and racial groups experience minor improvements due to the patients' contextual circumstances that include healthcare systems and the environment. 7 Approximately 23% of US Latinos live in poverty, about one-third lack healthcare coverage, have lower rates of education attainment, and limited English proficiency compromises the delivery of care that ultimately impacts clinical outcomes. 8,9 Data show that Latinos are 1.7 times more likely to be diagnosed with diabetes and three times more likely to start treatment for end-stage renal disease than non-Hispanic whites, with Latino women 1.5 times more likely to die of diabetes than non-Hispanic white women.…”

Section: Introductionmentioning

confidence: 99%